KPTI News and Press, Karyopharm Therapeutics Inc. From 08/04/22

Karyopharm Therapeutics, Inc. (KPTI) Q2 2022 Results Conference Call August 4, 2022 08:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Mike Mason - EVP, CFO ...

Karyopharm Therapeutics press release ( NASDAQ: KPTI ): Q2 GAAP EPS of -$0.62 misses by $0.01 . Revenue of $39.68M (+75.6% Y/Y) beats by $3.72M . XPOVIO (selinexor) Net Product Revenue of $29.0 Million, a 44% Increase Over Q2 2021 For further details see:...

Karyopharm Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress PR Newswire – Achieved Second Quarter 2022 Total Revenue of $39.7 Million , Up 76% Versus Second Quarter 2021; XPOVIO® (selinexor) Net Product Revenu...

Karyopharm Therapeutics ( NASDAQ: KPTI ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is -$0.64 (+9.9% Y/Y) and the consensus Revenue Estimate is $35.96M (+59.1% Y/Y). Over the last 3 months, EPS e...

Karyopharm to Participate at the 2022 Wedbush Pacgrow Healthcare Conference PR Newswire NEWTON, Mass. , Aug. 2, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, ...

Karyopharm to Report Second Quarter 2022 Financial Results on August 4, 2022 PR Newswire -- Conference Call Scheduled for Thursday, August 4, 2022 , at 8:00 a.m. ET -- NEWTON, Mass. , July 28, 2022 /PRNewswire/ -- Karyopharm Therapeut...

Commercial-stage biotech Karyopharm Therapeutics ( NASDAQ: KPTI ) and Italian pharma company Menarini Group announced on Thursday that the European Commission granted marketing authorization for a multiple myeloma therapy containing the oral exportin 1 inhibitor Nexpovio. ...

Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy PR Newswire – Based on Results from Phase 3 BOSTON...

Karyopharm Therapeutics ( NASDAQ: KPTI ) said eltanexor was granted fast track designation by the U.S. Food and Drug Administration (FDA) as monotherapy to treat patients with relapsed or refractory intermediate, high-, or very high-risk myelodysplastic syndromes (MDS...

Karyopharm Granted Regulatory Designations for Eltanexor for the Treatment of Myelodysplastic Syndromes PR Newswire – FDA Fast Track Designation and European Commission Orphan Medicinal Product Designation Underscore the Significant Need for New Treatm...